Robert Lehman
Psychiatry · Baltimore, MDNPI 1558461632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,422 of the $139,705 with a category attached, or 86.2%. 33 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 58.9% of the total. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $238.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$82K
- AbbVie$36K
- Teva Pharmaceuticals USA, Inc.$7K
- Ironshore Pharmaceuticals Inc.$5K
- Sunovion Pharmaceuticals Inc.$3K
- Corium, LLC$3K
- plus $4K from 27 others
Across 181 payments — averaging $4524.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$706K
- Teva Pharmaceuticals USA, Inc.$90K
- Bayer$23K
What the payments were for
- Consulting fees$4,3603%
- Speaking & faculty fees$120,42286%
- Travel & lodging$5,8734%
- Food & beverage$9,0036%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 206 | $82,343 |
| AbbVie(2 entities) | 98 | $35,891 |
| Teva Pharmaceuticals USA, Inc. | 21 | $7,449 |
| Ironshore Pharmaceuticals Inc. | 17 | $4,829 |
| Sunovion Pharmaceuticals Inc. | 19 | $2,996 |
| Corium, LLC | 33 | $2,683 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $564 |
| Otsuka America Pharmaceutical, Inc. | 21 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $318 |
| Neurocrine Biosciences, Inc. | 11 | $281 |
| Neos Therapeutics, LP | 18 | $245 |
| Alkermes, Inc. | 10 | $242 |
| Axsome Therapeutics, Inc. | 8 | $190 |
| Tris Pharma Inc | 9 | $173 |
| Bausch Health US, LLC | 9 | $170 |
| Vanda Pharmaceuticals Inc. | 7 | $138 |
| Lundbeck LLC | 7 | $136 |
| E.r. Squibb & Sons, L.L.C. | 5 | $133 |
| Johnson & Johnson | 7 | $117 |
| Collegium Pharmaceutical, Inc. | 5 | $97 |
| Idorsia Pharmaceuticals US Inc | 4 | $78 |
| Jazz Pharmaceuticals Inc. | 4 | $54 |
| Almatica Pharma LLC | 3 | $48 |
| Merck | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,705 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $16,496 |
| BelsomraSuvorexant | 14 | $8,465 |
| FetzimaLevomilnacipran Hcl | 13 | $6,335 |
| Oxcarbazepine | 63 | $3,595 |
| Olanzapine | 168 | $3,568 |
| Quetiapine Fumarate | 66 | $3,023 |
| Duloxetine Hcl | 113 | $2,560 |
| Divalproex Sodium | 23 | $2,224 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $2,203 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 31 | $1,879 |
| Bupropion XlBupropion Hcl | 97 | $1,747 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,743 |
| Gabapentin | 105 | $1,722 |
| Carbamazepine | 25 | $1,720 |
| Vilazodone Hcl | 15 | $1,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $35,891 | $22,83125 claims |
| MerckBelsomra | $45 | $8,46514 claims |
| Almatica Pharma LLCSertraline Hcl | $48 | $63569 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
- Chiadikaobi OnyikeBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.